Spanish biotech company Biohope has secured a €2 million grant from the Community of Madrid to drive the development of its innovative diagnostic device, MTX-CELL. This tool predicts the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis (RA), enabling personalized treatments from the outset. By optimizing therapy, MTX-CELL reduces the costs associated with ineffective treatments and improves patient outcomes.
This achievement was made possible with the support of PNO, whose expertise contributed to Biohope obtaining the prestigious Seal of Excellence from the European Innovation Council (EIC) Accelerator program. The Seal of Excellence recognizes high-potential projects of exceptional quality and relevance, even if they do not receive direct EU funding.
This year, the Comunidad de Madrid has allocated funds to support startups and SMEs through programs like the Seal of Excellence.
With this funding, Biohope will focus on the final development and validation phases of MTX-CELL, bringing this groundbreaking tool closer to clinical practice. The device is set to benefit patients, healthcare providers, and the broader healthcare system by:
This milestone highlights Biohope’s dedication to innovative healthcare solutions, the strategic support of PNO, and the Comunidad de Madrid’s commitment to fostering groundbreaking research and development.
10/06/2025
28/05/2025
10/04/2025
Discover how our specialists can drive your innovation
Select CountryBelgiumFranceGermanyGreeceItalyNorwayPortugalSpainThe NetherlandsUnited KingdomOther
I accept that the privacy statement is applicable
* Required fields
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Consider the environmental impact before printing this
Print